Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 137.96M | 138.41M | 140.93M | 137.28M | 115.94M | 93.73M |
Gross Profit | 108.48M | 109.16M | 112.85M | 112.09M | 100.45M | 82.86M |
EBITDA | 92.98M | 91.47M | 111.64M | 96.49M | 84.00M | 53.00M |
Net Income | 7.94M | 6.63M | 20.61M | -5.23M | -2.07M | -20.61M |
Balance Sheet | ||||||
Total Assets | 656.69M | 1.26B | 1.27B | 1.39B | 1.26B | 1.10B |
Cash, Cash Equivalents and Short-Term Investments | 1.84M | 6.82M | 26.40M | 4.02M | 7.21M | 5.51M |
Total Debt | 258.64M | 653.59M | 618.91M | 694.12M | 571.73M | 586.58M |
Total Liabilities | 286.13M | 700.57M | 661.89M | 744.20M | 625.91M | 643.15M |
Stockholders Equity | 340.22M | 534.13M | 583.58M | 632.98M | 622.78M | 444.81M |
Cash Flow | ||||||
Free Cash Flow | 16.16M | -25.07M | 58.39M | -79.66M | -132.69M | -184.27M |
Operating Cash Flow | 68.03M | 70.05M | 68.44M | 76.54M | 68.97M | 34.52M |
Investing Cash Flow | -70.14M | -45.94M | 67.62M | -137.25M | -194.66M | -223.67M |
Financing Cash Flow | 1.90M | -21.89M | -143.79M | 62.41M | 127.70M | 192.72M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | $495.91M | ― | -1.67% | 10.86% | 1.33% | -149.80% | |
69 Neutral | $571.93M | 30.55 | 10.15% | 7.18% | 0.95% | 15.07% | |
68 Neutral | $904.69M | ― | -13.96% | 1.08% | 5.33% | 10.68% | |
67 Neutral | $126.57M | 17.26 | 36.40% | 5.45% | 22.41% | 37.88% | |
66 Neutral | $1.32B | 37.80 | 2.46% | 6.65% | -2.94% | 46.24% | |
63 Neutral | $6.99B | 18.83 | -1.16% | 6.86% | 4.65% | -25.28% | |
58 Neutral | $527.39M | 232.27 | 1.45% | 8.39% | -1.66% | -86.24% |
On June 20, 2025, Global Medical REIT announced the transition of Jeffrey M. Busch from his role as Chief Executive Officer and President, effective June 23, 2025. Mark O. Decker, Jr. was appointed as the new CEO and President, bringing extensive experience in real estate investment and management. This leadership change is part of the company’s strategic efforts to enhance shareholder value and guide portfolio management and growth initiatives.
The most recent analyst rating on (GMRE) stock is a Buy with a $11.75 price target. To see the full list of analyst forecasts on Global Medical REIT stock, see the GMRE Stock Forecast page.
On May 28, 2025, Global Medical REIT announced a reduction in its quarterly cash dividend from $0.21 to $0.15 per share, effective for stockholders of record as of June 20, 2025, and payable on July 9, 2025. This strategic move aims to position the company for future growth by enhancing balance sheet flexibility and generating additional free cash flow to reduce leverage and improve capital costs, while ensuring a well-covered dividend for investors.
The most recent analyst rating on (GMRE) stock is a Buy with a $11.75 price target. To see the full list of analyst forecasts on Global Medical REIT stock, see the GMRE Stock Forecast page.
On May 14, 2025, Global Medical REIT Inc. conducted its annual meeting where stockholders elected seven directors to the board, approved executive compensation, and ratified Deloitte & Touche LLP as the accounting firm for 2025. These decisions reflect the company’s ongoing governance and operational strategies, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (GMRE) stock is a Buy with a $11.75 price target. To see the full list of analyst forecasts on Global Medical REIT stock, see the GMRE Stock Forecast page.